<DOC>
	<DOCNO>NCT02526888</DOCNO>
	<brief_summary>The main objective study investigate whether repeat administration cardiac medication ( diltiazem ) affect pharmacokinetics ( i.e. , amount time presence blood ) ACT-541468</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Diltiazem ACT-541468 Healthy Subjects</brief_title>
	<detailed_description>Because ACT-541468 appear mainly metabolize CYP3A4 , deem interest investigate potential influence diltiazem , well-known CYP3A4 inhibitor pharmacokinetic profile ACT-541468 . Safety concomitant administration two drug also assess</detailed_description>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Signed informed consent Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screen Healthy basis physical examination , cardiovascular assessment laboratory test Any contraindication study drug History presence disease condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study drug History narcolepsy cataplexy modify Swiss narcolepsy scale total score &lt; 0 Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>interaction</keyword>
</DOC>